Month: January 2018

Lexington Receives Approval to Commence Clinical Study

Lexington Biosciences is pleased to announce its recent application for Institutional Review Board (“IRB”) approval of its pilot clinical study at Diablo Clinical Research has been approved. 

Lexington Completes IRB Submission in Preparation for Clinical Study

Another milestone achieved as the Company moves towards HeartSentry human trials Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce it has completed its requisite documentation and submitted an application for Institutional Review Board (“IRB”) approval of its pilot clinical study. In preparation for commercialization of the

Read More

Lexington Biosciences Announces Exercise of Warrants

VANCOUVER, British Columbia, Jan. 11, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce that 5,497,500 share purchase warrants which were issued on November 24, 2016 and December 20, 2016 have been exercised on or before December 20, 2017 at a price of $0.30 per warrant

Read More

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News